Cancer vaccine NY-ESO-1 - Therion Biologics

Drug Profile

Cancer vaccine NY-ESO-1 - Therion Biologics

Alternative Names: Recombinant vaccinia/fowlpox NY-ESO-1 cancer vaccine - Therion Biologics

Latest Information Update: 05 Jan 2009

Price : $50

At a glance

  • Originator Therion Biologics
  • Developer Ludwig Institute for Cancer Research; Therion Biologics
  • Class Cancer vaccines; Peptide vaccines; Peptides; Saponins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Nov 2006 Clinical data have been added to the adverse events and Cancer pharmacodynamics as well as therapeutic trials sections
  • 04 Jul 2003 Data presented at the 39th Annual Meeting if the American Society of Clinical Oncology (ASCO-2003) have been added to the pharmacodynamics and Cancer therapeutic trials section
  • 19 Sep 2002 Therion Biologics has entered into a non-exclusive licensing agreement with Boehringer Ingelheim Pharmaceuticals for ICAM-1
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top